ABSTRACT
Renal cell carcinoma (RCC), the most common form of kidney cancer, is characteristic by difficult in diagnosis at an early stage, insensitivity to chemoradiotherapy, poor prognosis, etc.. Localized RCC is treated by surgery while advanced RCC is mainly treated by immunotherapy and targeted therapy. With the ongoing in-depth researches on targeted therapy in recent years, plenty of targeted drugs come into the market in succession. Cabozantinib has been approved for the treatment of advanced RCC in the first/second line setting. It′s safety profile and efficiency have been demonstrated in Ⅱ-Ⅲ clinical trials.
ABSTRACT
Renal cell carcinoma (RCC),the most common form of kidney cancer,is characteristic by difficult in diagnosis at an early stage,insensitivity to chemoradiotherapy,poor prognosis,etc. . Localized RCC is treated by surgery while advanced RCC is mainly treated by immunotherapy and targeted therapy. With the ongoing in-depth researches on targeted therapy in recent years,plenty of targeted drugs come into the market in succession. Cabozantinib has been approved for the treatment of advanced RCC in the first/ second line setting. It's safety profile and efficiency have been demonstrated in Ⅱ-Ⅲ clinical trials.